Pharmaceutical corporation Celgene acquired $15m worth of series B2 stock in US-based small molecule drug company Acetylon Pharmaceuticals on Thursday. Celgene will not however, hold licensing or marketing rights to drugs currently under development at Acetylon. Acetylon closed its series B round in June having raised $27m, while its series A round raised $9.25m over…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
